Global Uveitis Treatment Market Size, Share, Forecast Report, 2020-2027
The global uveitis treatment market was valued at $478 million in 2018, and is projected to reach $687 million by 2026, registering a CAGR of 4.6% from 2019 to 2026.
Uveitis is the inflammation of the middle layer of tissue in the eye wall uvea that consists of the iris, choroid, and ciliary body. Different forms of drug such as cycloplegic agents, anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others are used in treatment of uveitis. Different types of uveitis include anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis. The most common type of uveitis is an inflammation of the iris called iritis or anterior uveitis.
Increase in prevalence of uveitis and rise in awareness among patient population with increase in adoption of advanced therapeutics is expected to drive the uveitis treatment market growth. In addition, easy accessibility to uveitis therapeutics, rise in demand for uveitis medications, and surge in R&D activities to develop ideal uveitis therapeutics further fuel the market growth. However, unknown etiology and pathophysiology of uveitis is anticipated to hamper the market growth. Furthermore, untapped potential offered by developing economies present lucrative opportunities for the growth of the market during the forecast period. However, lack of specific treatment for uveitis disorder is expected to restrain the growth of the market.
Uveitis Treatment Market Segmentation
The global uveitis treatment market is segmented on the basis of drug class, disease type, distribution channel, and region. Based on drug class, the market is classified into anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others. Disease type such as anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis are covered in the report. According to distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Segment Review
Based on drug class, the uveitis treatment market is categorized into anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others. Currently, anti-inflammatory is major revenue contributing segment and is estimated to significantly grow during the forecast period, owing to adoption of anti-inflammatory as first line treatment for uveitis.
Anti-inflammatory medications are available in the form of eye drops, tablets, or injection form. Eye drops of anti-inflammatory drugs may not penetrate well to the back of the eye, thus this type of treatment is not preferred in posterior uveitis. In case of intermediate or posterior uveitis, and if topical corticosteroid hasn’t worked, corticosteroid injections or shot are used to reduce inflammation. On the other hand, immunotherapy & targeted therapies segment is expected to witness fastest market growth due to rise in demand for ideal therapeutics for treatment of uveitis. Immunosuppressant drugs such as azathioprine, cyclosporine, methotrexate, mycophenolate, and others are available in the uveitis treatment market.
According to disease type, the market is classified into anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis. The anterior uveitis segment is anticipated to depict a significant growth during the forecast period due to higher prevalence of uveitis. Anterior uveitis is most common type of uveitis characterized by an inflammation of the middle layer of the eye, it includes the iris and the adjacent tissue, known as the ciliary body.
Snapshot of Asia-Pacific Uveitis Treatment Market
Asia-Pacific presents lucrative opportunities for the key players operating in the uveitis treatment market, owing to growth in awareness regarding uveitis treatment and rise in adoption of uveitis treatment products. Moreover, improvement in healthcare infrastructure, rise in number of target population, developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare further contribute to the market growth. In addition, factors such as surge in focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the marketand high population base are also expected to drive the growth of the uveitis treatment market in Asia-Pacific.
The key players profiled in this report include AbbVie Inc., Alimera Sciences, Inc., Allergan Plc., Amgen Inc., Bausch Health Companies Inc. (Bausch & Lomb Incorporated), Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Mylan N.V., Novartis AG, and Santen Pharmaceutical Co., Ltd.
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers